GO:1990450 linear polyubiquitin binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990450 (linear polyubiquitin binding) is a molecular function describing the selective binding of proteins to M1-linked ubiquitin chains, in which the amino-terminal methionine (M1) of one ubiquitin is linked to the carboxy-terminal glycine (G76) of the next.
• Linear (M1-linked) polyubiquitin is generated by the LUBAC complex and is best known for scaffolding NF-kB signaling complexes through NEMO and other ubiquitin-binding domains.
• Reader proteins such as NEMO, A20 (via ZF7), ABIN-2, and Rad18 recognize linear chains with distinct structural mechanisms, often involving conformational changes or continuous ubiquitin-binding domains.
• Linear ubiquitination is not only a signaling event: it occurs at damaged lysosomes to locally activate NF-kB and control cell survival.
• Dysregulated linear polyubiquitin binding is linked to inflammatory signaling, cancer, and neurodegeneration, including TDP-43-positive inclusions in amyotrophic lateral sclerosis.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are powerful tools to dissect the causal roles of linear polyubiquitin readers and writers in disease.
Description
Linear polyubiquitin binding (GO:1990450) is the molecular function of selectively recognizing ubiquitin polymers in which the amino-terminal methionine (M1) of one ubiquitin is conjugated to the carboxy-terminal glycine (G76) of the next, producing a head-to-tail linear chain. Unlike K48- or K63-linked chains, linear chains adopt distinct conformational dynamics that create unique docking surfaces for reader proteins. This function is central to the assembly and regulation of NF-kB signaling platforms, where linear chains act as scaffolds that recruit NEMO and other components. Because linear polyubiquitin binding couples ubiquitin chain recognition to immune, inflammatory, and survival outputs, it has become a focal point for researchers studying signal transduction, host defense, and disease mechanisms. The LUBAC complex is the principal writer of M1-linked chains, and its activity is balanced by negative regulators such as A20, which binds linear chains through its zinc finger 7 domain to inhibit NF-kB activation. Beyond canonical NF-kB signaling, linear polyubiquitin binding has been observed in quality-control pathways at damaged lysosomes, where local linear ubiquitination triggers NF-kB activation and influences cell survival. In neurodegeneration, linear polyubiquitin chain modification of TDP-43-positive inclusions in amyotrophic lateral sclerosis suggests that this function contributes to proteinopathy. Understanding GO:1990450 therefore requires integrating structural biology, cell signaling, and disease models, and CRISPR-based cell models provide a direct route to test causality.
linear polyubiquitin binding At A Glance
| GO ID | GO:1990450 |
|---|---|
| GO term | linear polyubiquitin binding |
| Ontology | molecular_function |
| Synonym | M1-linked ubiquitin chain binding |
| Major function | Selective recognition of M1-linked (linear) ubiquitin polymers by reader proteins |
| Chain linkage | M1 of one ubiquitin to G76 of the next ubiquitin |
| Principal writer complex | LUBAC (linear ubiquitin chain assembly complex) |
| Representative readers | NEMO, A20 (ZF7), ABIN-2, Rad18 |
| Associated pathway | NF-kB signaling, lysosomal quality control, neurodegeneration |
| Disease relevance | Inflammatory signaling, cancer, amyotrophic lateral sclerosis |
What Is GO:1990450?
GO:1990450, linear polyubiquitin binding, is defined as binding to a linear polymer of ubiquitin in which the amino-terminal methionine (M1) of one ubiquitin molecule is linked to the carboxy-terminal glycine (G76) of the next. This is a molecular function term: it describes the ability of a protein to physically associate with M1-linked ubiquitin chains, not the enzymatic generation of those chains. The synonym M1-linked ubiquitin chain binding is often used interchangeably. Proteins that carry this function typically contain ubiquitin-binding domains or zinc finger modules that engage the linear chain with high selectivity, and in some cases binding induces conformational changes in the reader.
Why Is linear polyubiquitin binding Important in Cell Biology?
Linear polyubiquitin binding is important because it converts a specific ubiquitin chain linkage into a signaling platform that controls NF-kB activation, cell survival, and inflammatory responses. The unique M1 linkage creates conformational and dynamic properties that distinguish linear chains from other polyubiquitin topologies, allowing reader proteins to discriminate between them. This discrimination is essential for proper immune signaling and for preventing excessive or mislocalized NF-kB activity, as illustrated by A20-mediated inhibition through its zinc finger 7 domain. Moreover, linear polyubiquitin binding occurs in non-canonical contexts such as damaged lysosomes, where it locally activates NF-kB and influences whether cells survive. In disease, linear polyubiquitin chain modification of TDP-43 inclusions in ALS highlights a role in neurodegeneration. Thus, GO:1990450 sits at the intersection of ubiquitin biology, signal transduction, and human disease, making it a high-value target for mechanistic and therapeutic research.
• Defines a distinct ubiquitin code readout: M1-linked chains are structurally and dynamically different from K48- or K63-linked chains, enabling specific recognition.
• Scaffolds NF-kB signaling: linear chains recruit NEMO and other factors to assemble active signaling complexes.
• Controls inflammatory gene expression: LUBAC-mediated linear ubiquitination and its readers are central to NF-kB activation.
• Provides a negative feedback node: A20 binds linear chains via ZF7 to inhibit LUBAC-mediated NF-kB activation.
• Links ubiquitin recognition to lysosomal quality control and cell survival decisions.
• Implicated in neurodegeneration: linear polyubiquitin chain modification occurs on TDP-43-positive inclusions in ALS.
• Offers structural targets: NEMO, ABIN-2, and Rad18 illustrate diverse linear-chain binding mechanisms.
• Enables CRISPR-based causality studies of readers, writers, and erasers in disease models.
• Relevant to cancer biology through NF-kB-driven survival and proliferation programs.
• Supports development of selective probes and inhibitors targeting linear ubiquitin signaling.
Molecular Mechanism of linear polyubiquitin binding
Recognition of the M1 linkage
In simple terms: Reader proteins have specialized pockets that fit the unique head-to-tail connection of linear ubiquitin chains.
Linear polyubiquitin chains are formed by linking the amino-terminal methionine (M1) of one ubiquitin to the carboxy-terminal glycine (G76) of the next, creating a distinct topology. The dynamics of linear polyubiquitin have been characterized, revealing conformational flexibility that differs from other chain types and likely contributes to selective reader engagement. Proteins that bind linear chains must recognize this M1 linkage, often through ubiquitin-binding domains or zinc finger modules that contact the chain in a linkage-specific manner.
Conformational change in the reader: NEMO
In simple terms: When NEMO grabs a linear ubiquitin chain, it changes shape, which helps assemble the NF-kB signaling machine.
Evidence supports M1-linked polyubiquitin-mediated conformational change in NEMO, indicating that binding is not a passive event but can reorganize the reader to promote signaling. This structural plasticity is thought to facilitate recruitment of downstream kinases and assembly of active NF-kB complexes.
Zinc finger recognition: A20 ZF7
In simple terms: A20 uses a zinc finger module to grab linear ubiquitin chains and shut down NF-kB signaling.
A20 inhibits LUBAC-mediated NF-kB activation by binding linear polyubiquitin chains via its zinc finger 7 domain. This provides a paradigm for how a single ubiquitin-binding module can confer linkage specificity and negative regulation of linear ubiquitin signaling.
Continuous ubiquitin-binding domains: ABIN-2 and Rad18
In simple terms: Some proteins use multiple linked ubiquitin-binding domains to wrap around linear chains.
Structural insights into linear tri-ubiquitin recognition by ABIN-2 reveal how continuous ubiquitin-binding domains engage the chain. Similarly, molecular determinants of polyubiquitin recognition by continuous ubiquitin-binding domains of Rad18 have been defined, showing that tandem domains can achieve linkage-specific binding. These examples illustrate diversity in how GO:1990450 is executed at the molecular level.
Local signaling at damaged lysosomes
In simple terms: When lysosomes are damaged, linear ubiquitin chains form on them and switch on local NF-kB to help the cell survive.
Linear ubiquitination at damaged lysosomes induces local NF-kB activation and controls cell survival, demonstrating that linear polyubiquitin binding can occur on organelle surfaces and drive spatially restricted signaling. This expands the functional contexts of GO:1990450 beyond canonical plasma-membrane or cytosolic NF-kB signaling.
Regulation by writers and erasers
In simple terms: The amount of linear ubiquitin chains is controlled by enzymes that add or remove them, tuning how much binding occurs.
LUBAC-mediated linear ubiquitination is the principal source of M1-linked chains, and its activity is balanced by negative regulators such as A20. The interplay between writers, readers, and erasers determines the steady-state level of linear chains and thus the extent of linear polyubiquitin binding.
Key Genes Involved in GO:1990450 linear polyubiquitin binding
The following genes and proteins are central to linear polyubiquitin binding (GO:1990450), either as readers, writers, or regulators of M1-linked ubiquitin chains.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NEMO (IKBKG) | Reader of linear polyubiquitin; undergoes conformational change upon binding | Core NF-kB signaling scaffold; structural and functional studies |
| A20 (TNFAIP3) | Binds linear polyubiquitin via ZF7 to inhibit LUBAC-mediated NF-kB activation | Negative regulator; inflammation and autoimmunity models |
| ABIN-2 (TNIP2) | Recognizes linear tri-ubiquitin via continuous ubiquitin-binding domains | Structural basis of linear chain recognition |
| Rad18 | Contains continuous ubiquitin-binding domains that recognize polyubiquitin | Molecular determinants of linkage-specific binding |
| HOIP (RNF31) | Catalytic subunit of LUBAC; generates M1-linked chains | Writer of linear ubiquitin; NF-kB and disease models |
| HOIL-1 (RBCK1) | Component of LUBAC; supports linear ubiquitination | LUBAC function and tissue homeostasis |
| Sharpin (SHARPIN) | Component of LUBAC; stabilizes the complex | LUBAC regulation and inflammatory signaling |
| TDP-43 (TARDBP) | Forms inclusions modified by linear polyubiquitin in ALS | Neurodegeneration and proteinopathy models |
| NF-kB subunits (RELA, NFKB1) | Downstream effectors activated by linear ubiquitin signaling | Inflammation and survival readouts |
| Lysosomal proteins (context-dependent) | Sites of linear ubiquitination at damaged lysosomes | Organelle-specific NF-kB activation and survival |
| Ubiquitin (UBB/UBC) | Building block of linear chains | Chain topology and dynamics studies |
| Proteasome-associated factors | May intersect with linear chain turnover | Quality control and signaling crosstalk |
| Autophagy regulators | Linked to lysosomal damage responses | Cell survival decisions |
| Innate immune sensors | Upstream of NF-kB activation | Host defense and inflammation |
| Kinases (IKK complex) | Activated downstream of linear ubiquitin scaffolds | NF-kB pathway readouts |
| Deubiquitinases (e.g., CYLD, OTULIN) | Remove or edit linear chains | Negative regulation of linear ubiquitin signaling |
| Inflammation-associated cytokines (TNF, IL-1) | Induce LUBAC-dependent signaling | Stimulus-response models |
How Is linear polyubiquitin binding Regulated?
Linear polyubiquitin binding is regulated at multiple levels. The abundance of M1-linked chains is controlled by the LUBAC complex, which writes linear ubiquitin, and by negative regulators such as A20, which binds linear chains via ZF7 to inhibit LUBAC-mediated NF-kB activation. Deubiquitinases that cleave linear chains also shape the pool available for binding. At the reader level, conformational changes such as those observed in NEMO upon M1-linked polyubiquitin binding can modulate signaling output. Spatially, linear ubiquitination at damaged lysosomes creates local signaling hubs that activate NF-kB and influence cell survival, indicating that subcellular context is a key regulatory layer. Together, these mechanisms tune the intensity and duration of linear polyubiquitin-dependent signaling.
linear polyubiquitin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TNFAIP3 (A20) | Inflammatory and autoimmune signaling; negative regulation of NF-kB | Knockout or point-mutation cell lines; NF-kB reporter assays |
| RNF31 (HOIP) | Cancer and inflammatory signaling; LUBAC-mediated linear ubiquitination | Knockout and overexpression models; cytokine stimulation |
| TARDBP (TDP-43) | Amyotrophic lateral sclerosis; TDP-43-positive inclusions | Knock-in or overexpression neuronal models; inclusion analysis |
| IKBKG (NEMO) | NF-kB signaling; conformational change upon linear chain binding | Point-mutation knock-in; structural and signaling assays |
| Lysosomal damage response genes | Cell survival and organelle quality control | Knockout cells with lysosomal damage inducers; NF-kB readouts |
Inflammatory and autoimmune signaling
Linear polyubiquitin binding is central to NF-kB activation, and its dysregulation is linked to inflammatory and autoimmune conditions. A20, a negative regulator that binds linear chains via ZF7, restrains LUBAC-mediated NF-kB activation, and loss of this control can promote excessive inflammation. LUBAC-mediated linear ubiquitination is implicated in tissue homeostasis and disease, underscoring its importance in immune regulation.
Cancer
Because linear polyubiquitin binding scaffolds NF-kB survival signaling, alterations in this pathway can contribute to cancer cell survival and proliferation. LUBAC components and their readers are therefore of interest as potential therapeutic targets in NF-kB-driven malignancies.
Neurodegeneration
Linear polyubiquitin chain modification of TDP-43-positive neuronal cytoplasmic inclusions has been observed in amyotrophic lateral sclerosis, linking GO:1990450 to proteinopathy and neurodegeneration. This suggests that linear ubiquitin recognition may participate in the handling or toxicity of misfolded protein aggregates.
Lysosomal damage and cell survival
Linear ubiquitination at damaged lysosomes induces local NF-kB activation and controls cell survival, connecting linear polyubiquitin binding to organelle quality control and stress responses. Defects in this process could influence cell fate decisions in disease contexts.
From linear polyubiquitin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a reader abolish linear polyubiquitin-dependent NF-kB activation? | CRISPR knockout cell line with cytokine stimulation and NF-kB reporter |
| Does a specific zinc finger or ubiquitin-binding domain mediate linear chain binding? | Point-mutation knock-in of the binding domain |
| Can a tagged reader be used to map linear ubiquitin binding sites? | Knock-in of an epitope tag at the endogenous locus |
| Does overexpression of a writer increase linear ubiquitin chains and signaling? | Overexpression cell model with chain-specific detection |
| Is linear ubiquitination at damaged lysosomes required for survival? | Knockout or knock-in cells treated with lysosome-damaging agents |
| Does linear polyubiquitin modification occur on TDP-43 inclusions? | Overexpression or knock-in neuronal models with inclusion staining |
How to Study the linear polyubiquitin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NF-kB reporter assay | Transcriptional activity downstream of linear ubiquitin signaling | Knockout and point-mutation validation |
| Immunoblotting | Protein levels and modification states of pathway components | Signaling activation and reader expression |
| Structural biology (crystallography, NMR) | Atomic details of linear chain recognition | Mechanistic studies of NEMO, ABIN-2, Rad18 |
| Molecular dynamics simulation | Conformational dynamics of linear polyubiquitin | Chain topology and flexibility |
| Immunofluorescence imaging | Subcellular localization of linear ubiquitin and NF-kB | Lysosomal damage and organelle signaling |
| Immunohistochemistry | Tissue distribution of linear polyubiquitin modifications | ALS and neurodegeneration studies |
| Co-immunoprecipitation | Physical interaction between readers and linear chains | Binding domain mapping |
| CRISPR screening | Genes required for linear ubiquitin-dependent phenotypes | Pathway discovery and validation |
Structural and biophysical analysis
Structural studies such as those on NEMO, ABIN-2, and Rad18 reveal how proteins recognize linear ubiquitin chains. Biophysical approaches including NMR and molecular dynamics have been used to characterize the dynamics of linear polyubiquitin, providing insight into linkage-specific recognition.
Cell signaling assays
NF-kB reporter assays, immunoblotting for IKK activation, and cytokine stimulation are standard methods to measure the functional consequences of linear polyubiquitin binding. These assays can be combined with knockout or point-mutation cell lines to test causality.
Imaging and organelle-specific studies
Imaging of linear ubiquitination at damaged lysosomes allows spatial dissection of local NF-kB activation and survival outcomes. Co-localization with lysosomal markers and chain-specific probes is typically used.
Neuropathology and inclusion analysis
Detection of linear polyubiquitin chain modification on TDP-43-positive inclusions in ALS tissue or models provides disease-relevant readouts. Immunohistochemistry and biochemical fractionation are commonly employed.
How CRISPR Can Be Used to Study GO:1990450 linear polyubiquitin binding
Knockout
CRISPR knockout of readers such as NEMO, A20, or LUBAC components can abolish or enhance linear polyubiquitin-dependent signaling, providing causal evidence for GO:1990450 in NF-kB activation and cell survival. Knockout of lysosomal damage response genes can test the role of linear ubiquitination at organelles.
Point Mutation
Point mutations in ubiquitin-binding domains, such as the zinc finger 7 of A20 or the linear chain-binding interface of NEMO, can selectively disrupt linear polyubiquitin binding without deleting the whole protein. These models are ideal for dissecting domain-specific functions.
Knock-in
Knock-in of epitope tags or fluorescent reporters at endogenous loci enables tracking of linear ubiquitin readers and their localization in real time. Knock-in of disease-associated mutations can model how altered linear polyubiquitin binding contributes to pathology.
Overexpression
Overexpression of LUBAC components or readers can amplify linear ubiquitin signaling and reveal gain-of-function phenotypes. Overexpression of TDP-43 in neuronal models can induce inclusions modified by linear polyubiquitin, linking GO:1990450 to neurodegeneration.
How EDITGENE Supports linear polyubiquitin binding Research
Researchers studying linear polyubiquitin binding-related genes often need to determine whether a candidate gene is causally involved in NF-kB signaling, lysosomal quality control, or neurodegeneration. EDITGENE provides publication-ready CRISPR cell models and screening services to test these hypotheses directly.
Contact EDITGENE today to design your custom CRISPR model for linear polyubiquitin binding research.
Frequently Asked Questions About linear polyubiquitin binding
What is linear polyubiquitin binding?
Linear polyubiquitin binding (GO:1990450) is the molecular function of selectively binding to ubiquitin polymers in which the amino-terminal methionine (M1) of one ubiquitin is linked to the carboxy-terminal glycine (G76) of the next.
What is the GO ID for linear polyubiquitin binding?
The Gene Ontology ID is GO:1990450, with the synonym M1-linked ubiquitin chain binding.
What genes are involved in linear polyubiquitin binding?
Key genes include NEMO (IKBKG), A20 (TNFAIP3), ABIN-2 (TNIP2), Rad18, and LUBAC components HOIP (RNF31), HOIL-1 (RBCK1), and Sharpin (SHARPIN).
How is linear polyubiquitin different from K48 or K63 chains?
Linear chains use M1-G76 linkages, creating distinct conformational dynamics and recognition surfaces compared with K48- or K63-linked chains.
What is the role of linear polyubiquitin binding in NF-kB signaling?
Linear chains scaffold NF-kB signaling by recruiting NEMO and other factors, and binding can induce conformational changes that promote pathway activation.
How does A20 regulate linear polyubiquitin signaling?
A20 binds linear polyubiquitin chains via its zinc finger 7 domain to inhibit LUBAC-mediated NF-kB activation.
Is linear polyubiquitin binding involved in disease?
Yes, it is linked to inflammatory signaling, cancer, and neurodegeneration, including TDP-43-positive inclusions in ALS.
What experimental models are used to study linear polyubiquitin binding?
CRISPR knockout, point-mutation, knock-in, and overexpression cell models, combined with NF-kB reporters, imaging, and structural methods, are commonly used.
Can linear ubiquitination occur at damaged lysosomes?
Yes, linear ubiquitination at damaged lysosomes induces local NF-kB activation and controls cell survival.
What methods detect linear polyubiquitin binding?
Methods include structural biology, molecular dynamics, immunoblotting, immunofluorescence, co-immunoprecipitation, and CRISPR screens.
Conclusion
GO:1990450, linear polyubiquitin binding, defines a specialized molecular function that reads the M1-linked ubiquitin code to control NF-kB signaling, organelle quality control, and cell survival. Its structural and dynamic basis is increasingly well understood through studies of NEMO, A20, ABIN-2, and Rad18. Because dysregulation of this function is linked to inflammation, cancer, and neurodegeneration, it represents a compelling area for mechanistic and therapeutic research. CRISPR-based cell models and screening approaches offer robust tools to establish causality and to identify new components of this pathway.
References
- 1. Zein L et al.. 2025. Linear ubiquitination at damaged lysosomes induces local NFKB activation and controls cell survival.. Autophagy 21(5):1075-1095 PMID: 39744815
- 2. Jussupow A et al.. 2020. The dynamics of linear polyubiquitin.. Sci Adv 6(42) PMID: 33055165
- 3. Hauenstein AV et al.. 2017. Evidence for M1-Linked Polyubiquitin-Mediated Conformational Change in NEMO.. J Mol Biol 429(24):3793-3800 PMID: 29111346
- 4. Verhelst K et al.. 2012. A20 inhibits LUBAC-mediated NF-κB activation by binding linear polyubiquitin chains via its zinc finger 7.. EMBO J 31(19):3845-55 PMID: 23032186
- 5. Lin SM et al.. 2017. Structural Insights into Linear Tri-ubiquitin Recognition by A20-Binding Inhibitor of NF-κB, ABIN-2.. Structure 25(1):66-78 PMID: 27916521
- 6. Thach TT et al.. 2015. Molecular determinants of polyubiquitin recognition by continuous ubiquitin-binding domains of Rad18.. Biochemistry 54(12):2136-48 PMID: 25756347
- 7. Nakayama Y et al.. 2020. Linear Polyubiquitin Chain Modification of TDP-43-Positive Neuronal Cytoplasmic Inclusions in Amyotrophic Lateral Sclerosis.. J Neuropathol Exp Neurol 79(3):256-265 PMID: 31951008
- 8. Sasaki K et al.. 2023. LUBAC-mediated linear ubiquitination in tissue homeostasis and disease.. J Biochem 174(2):99-107 PMID: 37279649
